inflammatory breast carcinoma
inflammatory breast carcinoma
Explore linked clinical trials. Standard reference: MONDO:000680421 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TRUDI: TDXD+Durva in HER2+/Low IBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, inflammatory breast carcinoma, invasive breast carcinoma, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-10-09 | NCT05795101 | |
| Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial | Neoplasms by Site, Skin and Connective Tissue Diseases, breast carcinoma, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Recruiting | Not applicable | 2026-10-06 | NCT07474090 | |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | Edema, Erythema, Neoplasms by Site, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, breast carcinoma, breast disorder, breast neoplasm, inflammatory breast carcinoma, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-10-06 | NCT02876107 | |
| Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | Neoplasms by Site, Neoplasms, Second Primary, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, invasive breast carcinoma, neoplasm, skin disorder | Recruiting | Not stated | 2026-10-06 | NCT00477100 | |
| Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements | Hemic and Lymphatic Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, lymphatic system disorder, lymphedema, neoplasm, skin disorder | Recruiting | Not stated | 2026-10-02 | NCT07855627 | |
| Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-29 | NCT03598257 | |
| Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer | Carcinoma, Ductal, Carcinoma, Lobular, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast cancer, breast disorder, breast ductal adenocarcinoma, breast neoplasm, carcinoma, epithelial neoplasm, inflammatory breast carcinoma, male breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT00295893 | |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Not applicable | 2026-09-09 | NCT04030507 | |
| Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | Edema, Erythema, Neoplasms by Site, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-07-15 | NCT02411656 | |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-07-06 | NCT02623972 | |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, bilateral breast carcinoma, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-06-30 | NCT03012100 | |
| Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-06-11 | NCT02971748 | |
| Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-06-10 | NCT03202316 | |
| Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Not applicable | 2026-05-26 | NCT03941756 | |
| FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients. | Body Weight, Neoplasms by Site, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, nutritional disorder, obesity disorder, overnutrition, skin disorder | Active, not recruiting | Not applicable | 2026-05-18 | NCT04200768 | |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-03-30 | NCT01525966 | |
| Onvansertib + Paclitaxel In TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, inflammatory breast carcinoma, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-11 | NCT05383196 | |
| Refining Local-Regional Therapy for IBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Recruiting | Not applicable | 2025-12-29 | NCT04636710 | |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-09-12 | NCT03515798 | |
| Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Not yet recruiting | Not applicable | 2024-01-23 | NCT06131632 | |
| Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients | Carcinoma, Ductal, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast ductal adenocarcinoma, breast mucinous carcinoma, breast neoplasm, carcinoma, epithelial neoplasm, inflammatory breast carcinoma, invasive tubular breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 / Phase 3 | 2023-08-29 | NCT02221999 |